Neurohormonal activation in populations susceptible to heart failure.
Arnlöv
Johan
J
National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA, USA.
Vasan
Ramachandran S
RS
D002316:Cardiotonic Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology*; D002395:Catecholamines / Q000378:metabolism; D016232:Endothelins / Q000378:metabolism; D006333:Heart Failure / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000378:metabolism / Q000503:physiopathology; D017379:Hypertrophy, Left Ventricular / Q000378:metabolism / Q000503:physiopathology; D009203:Myocardial Infarction / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D045265:Natriuretic Peptides / Q000378:metabolism; D018377:Neurotransmitter Agents / Q000378:metabolism*; D012084:Renin-Angiotensin System; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology
D002316:Cardiotonic Agents; D002395:Catecholamines; D016232:Endothelins; D045265:Natriuretic Peptides; D018377:Neurotransmitter Agents